EMAIL THIS PAGE TO A FRIEND

Journal of diabetes investigation

Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.


PMID 27180954

Abstract

To assess the efficacy and safety of acetyl-L-carnitine (ALC) on diabetic peripheral neuropathy compared with methylcobalamin (MC). This was a multicenter, randomized, parallel-group, double-blind, double-dummy, positive-controlled, non-inferior phasexa0II clinical trial. Diabetic patients with abnormal nerve conduction test results were randomized in a 1:1 ratio to receive oral ALC 500xa0mg t.i.d. or MC 0.5xa0mg t.i.d. for 24xa0weeks. The neuropathy symptom score, neuropathy disability score and neurophysiological parameters were measured during follow up. A total of 232 patients were randomized (ALC nxa0=xa0117, MC nxa0=xa0115), 88% of which completed the trial. At weekxa024, patients from both groups had significant reductions in both neuropathy symptom score and neuropathy disability score with no significant difference between two groups (neuropathy symptom score reduction: ALC vs MC 2.35xa0±xa02.23, Pxa0

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A6706
O-Acetyl-L-carnitine hydrochloride, ≥99% (titration), powder
C9H17NO4 · HCl